In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. - Wikidata - wikimedia - TriplyDB

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.

http://www.wikidata.org/entity/Q39954638

about

Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging Targeted therapy using nanotechnology: focus on cancer Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine.Clinical Translation of Nanomedicine.Imaging and drug delivery using theranostic nanoparticles Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity.Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice Optimizing Liposomal Cisplatin Efficacy through Membrane Composition Manipulations.Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.Biological rationale for the design of polymeric anti-cancer nanomedicines.Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.Anthracycline dose intensification in young adults with acute myeloid leukemia.Improving nucleoside analogs via lipid conjugation: Is fatter any better?A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways.DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption.Development of cytarabine prodrugs and delivery systems for leukemia treatment.Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo.Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms.Novel and emerging drugs for acute myeloid leukemia Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia.Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications.Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy.Novel therapeutics in acute myeloid leukemia.Materials innovation for co-delivery of diverse therapeutic cargos.Novel drugs for older patients with acute myeloid leukemia.Nanomedicine: a pharma perspective.Nanomedicine strategies for hematological malignancies: what is next?Programmable nanomedicine: synergistic and sequential drug delivery systems.Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment.Pleiotropic Role of Dietary Phytochemicals in Cancer: Emerging Perspectives for Combinational Therapy.

P2860

Q26778234-5A81CC30-79D7-41B1-85D5-4785894C971E Q27023361-14B5BFEF-2EDD-4796-B391-71E8F6A4BE2D Q28077848-605711DB-7F29-41BB-AD15-97EAF9CE8F0E Q28818166-5D709675-C1BD-4595-BCDC-896273396A9F Q30279055-D360A837-8E2C-46FE-9F13-492B7A40CED2 Q30355939-046358A9-BDEA-4A88-9BD6-0E276254541D Q30449480-34F84D0B-9C7A-4730-A843-A35B30F83E1B Q30456053-5DB71F9E-92E2-49B6-BE21-A3783F787C3D Q33598842-54F8B354-8872-48E7-8EBF-FD10A3901E15 Q33859472-075BE1CB-D93A-41A0-8B27-D3EEFB4F9C2F Q34543909-5473D82E-D17D-4589-BF4D-385FB6F67AD3 Q34693012-73A706C2-7F49-4BE0-984B-9BB2DE63AF4E Q35556561-470B77B4-5CCC-40CE-B9E2-181B82C030F7 Q35692141-099CD03C-7BD0-49D4-AA8D-1776C559C889 Q35751958-2CD6D2F1-2D15-4DC5-9478-21E692AA0111 Q35905061-65293001-D20C-4CF7-926A-EE984E9AD757 Q36160333-DA7E1FD1-885A-40F8-832A-D6F6558B7D52 Q36219674-6ABE75ED-D29F-4749-92CC-81BFA7D031F8 Q36612663-98DC190F-6043-42F8-B1B4-FD3486EBB256 Q36706248-DED7C9F5-7ADC-4005-94BD-5CD8FC9FB602 Q36767541-496A4851-628D-4DB7-A82E-5C1DBF59EC86 Q37621452-D25DA0AB-3C87-4F52-B1D1-7A6E3B9FA1CB Q37709177-808D2651-692B-4AC6-9314-8CDA9CA677B7 Q37801934-D02EB435-C3A8-46F1-8300-66994CD22298 Q37813687-4D85688D-2949-4340-9D86-228B957839BB Q37938830-EA10BA0F-16DF-484B-9B6A-B22431BF63D5 Q38000711-CBAACA2E-C727-4834-A221-F3C7E1C536C2 Q38042705-B0E6BCB2-88B4-48E7-A1C2-47D689E35BA6 Q38098301-5F2594E5-2278-452B-B5A1-163EEBEF9CF9 Q38103753-F6117B8B-7C93-438A-8759-695684349D59 Q38155455-601B745C-8D04-4CD4-A9D2-33AC4055D01B Q38183852-46F52EB3-0B3D-451F-B800-E2B26F8D4044 Q38196346-28D44576-84C0-45A6-9F1A-309757B5FE04 Q38211033-76300CE6-8025-4BE9-845B-268E85D4FBE4 Q38241761-6D7F3972-C48B-49D4-83CF-C20406424220 Q38246663-028F3790-9C49-4A3A-9E7D-F5D604784B71 Q38270098-21268F9D-4F80-4115-B219-45C75F422B86 Q38336134-8E3B45B6-3CCF-44FD-A9D7-E1EBFD0521E0 Q38403675-C14A8E02-FDF6-4F82-918C-E2066F6F23EB Q38584742-65E5B0F0-25E3-4341-9FF8-BB606E18661B

P2860

In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy.

http://www.wikidata.org/entity/Q39954638

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

In vivo maintenance of synergi ...... enhances therapeutic efficacy.

@en

In vivo maintenance of synergi ...... enhances therapeutic efficacy.

@nl

type

label

In vivo maintenance of synergi ...... enhances therapeutic efficacy.

@en

In vivo maintenance of synergi ...... enhances therapeutic efficacy.

@nl

prefLabel

In vivo maintenance of synergi ...... enhances therapeutic efficacy.

@en

In vivo maintenance of synergi ...... enhances therapeutic efficacy.

@nl

P1433

Q39954638-F36661FB-3959-4085-B68B-C7B17147C3F8

P1476

Q39954638-03A512AF-6E39-491E-872E-F9F466091861

P2093

Q39954638-80AE242D-1B4C-4933-A6F0-1711BB55C66E

Q39954638-87B80B45-DFB8-42F5-B36F-CCA76A9F7A2E

Q39954638-9043E315-7CBA-4BC0-A4AA-51311A9EA987

Q39954638-A1FDE5DD-0974-4B5F-B8B4-EF38AC8BEB45

Q39954638-D783BE15-2DA0-4828-8D02-4DE33BDCB820

Q39954638-E43E7EBC-FB7F-4E78-A280-994A734880A5

Q39954638-EC9C6376-5FDB-4C2C-944E-B38FE70FBB4D

Q39954638-F7660590-098B-47A3-9CA1-EA276AB4F1F2

P304

Q39954638-063A21FF-AB1A-4B02-8790-BACD40C66F97

P31

Q39954638-A9BDB804-5B7B-48CB-8EF1-86D110F1E17C

P356

Q39954638-69873780-0A04-48C2-B6FB-D2EB08DD9E13

P433

Q39954638-4C9C1F0F-D6AA-4D6A-B939-73217D7230B3

P478

Q39954638-62BD51CD-4D58-465B-88F1-3BB130ABAB18

P50

Q39954638-9CC8FC75-47A1-4BC6-A0E4-1BCD8C5689E4

P577

Q39954638-16BAE770-2AE8-4193-9CA4-1F28659F8D00

P698

Q39954638-3665223C-E72C-4945-A66E-81C7B2EC5779

P356

J.LEUKRES.2008.06.028

P1433

Leukemia Research

P1476

In vivo maintenance of synergi ...... enhances therapeutic efficacy

@en

P2093

Lawrence Mayer

http://www.w3.org/2001/XMLSchema#string

Natalia Zisman

http://www.w3.org/2001/XMLSchema#string

Natashia Harasym

http://www.w3.org/2001/XMLSchema#string

Paul Tardi

http://www.w3.org/2001/XMLSchema#string

Pierrot Harvie

http://www.w3.org/2001/XMLSchema#string

Sharon Johnstone

http://www.w3.org/2001/XMLSchema#string

Sherwin Xie

http://www.w3.org/2001/XMLSchema#string

Troy Harasym

http://www.w3.org/2001/XMLSchema#string

P304

129-139

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.LEUKRES.2008.06.028

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18676016

http://www.w3.org/2001/XMLSchema#string